By Karuna Jaggar, Executive Director
Far from giving patients new rights, the so-called “Right to Try” bill before the House actually takes away essential safeguards that protect patients.
So-called “Right to Try” bills are another of the current administration’s relentless efforts to undercut important federal agencies and roll back regulations. In fact, it’s the only legislation that was singled out and specifically mentioned by President Trump in his State of The Union speech in January. This misguided effort is now up for a vote in the House.
So much is at stake! Essential patient safeguards are on the line!
Removing Food and Drug Administration (FDA) oversight from access to experimental drugs is a dangerous. So-called “Right to Try” bills open the door to predatory scams that exploit vulnerable patients by charging as much as they want for drugs that may actually hasten their death. All while also depriving doctors and scientists from learning whether a drug is effective or not. This smoke-and-mirrors legislation promises a quick fix—for a problem that doesn’t exist. The FDA already supports access to experimental drugs for desperately ill and dying patients.
The truth is the FDA is not the barrier to accessing experimental treatments and undermining the agency won’t lead to better, more affordable, or more effective treatments for women at risk of and living with breast cancer.
Call the Capitol Switchboard NOW. Tell your Representative to Vote NO: (202) 224-3121